INNOVATION PATHWAYS, LLC

Biotech · Private

IPW-5371, a small molecule TGF inhibitor therapeutic to treat delayed effects of acute radiation exposure (DEARE)

Claim this profile

Follows are private to you and power your alerts

Updated

Sector
Biotech
Total capital
$9.8M
Federal grants
$600K
2 awards · 2018–2019
Rank in peer group#164 of 502
Private capital raised
None on recordNo Form D filings on SEC EDGAR. Some raises are not filed.
Federal contracts
$9.2M
2 awards · Health and Human S
Rank in Biotech#61 of 4373
Granted patents
None on recordNo USPTO grants. Applications publish after 18 months.

Capital timeline

201820192020202120222023FEDERAL ↑EQUITY ↓Cumulative $9.8M$5.6M$300K$300K$3.6M
201820192020202120222023FEDERAL ↑EQUITY ↓Cumulative $9.8M$5.6M$300K$300K$3.6M

Latest events

  • Federal contractHealth and Human S · The Pharmacological Development Of IPW-5371 Fumarate As A Radiation Medical Countermeasure For The Treatment Of Delayed Radiation Lung Injury Under The Fda Animal Rule$3.6M
  • Federal grantHealth and Human S · Phase I · Evaluation of IPW-5371, a TGFbRI kinase inhibitor, dosed as a single agent or in combination with G-CSF, as a medical countermeasure against the delayed effects of total body irradiation in mice$300K
  • Federal grantHealth and Human S · Phase I · Evaluation of IPW-5371, a TGFbRI kinase inhibitor, dosed as a single agent or in combination with G-CSF, as a medical countermeasure against the delayed effects of total body irradiation in mice$300K
  • Federal contractHealth and Human S · Igf::ot::igf Acute Radiation-induced Lung Injury In The Rhesus Macaque And Its' Treatment BYIPW-5371, A Small Molecule Inhibitor Of Tgf# RECEPTOR-1 Kinase$5.6M

Node area is scaled to amount. Form D reports securities sold, which can differ from an announced round; filings are numbered in the order they were made.

Standing among 502 peers

Line = median

Biotech · Molecule

  • Federal grants#164 · top 33%

Cumulative measures favor older companies. Rankings describe position today, not outcome. Below the median, ranks show as a band rather than a number.

Founders and team

No founders are linked to this company yet.

Founders appear once a person is matched to the company through its own patents, grants or filings. We never infer people from social profiles.

Checked: USPTO inventors; federal award principal investigators; SEC Form D related persons · Oct 23, 2026

Claim this profile to add your team

What it has protected

No granted patents are on record.

USPTO usually publishes applications 18 months after filing, so recent applications may not be visible yet. Patents assigned under a different entity name won’t match.

Checked: USPTO granted patents and published applications · Oct 23, 2026

Regulatory activity · Biotech

Sector-level, not company-level

Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.

Sources

Federal grants from SBIR/STTR, NIH, NSF and DoD records. Federal contracts from USAspending.gov. Private capital from SEC Form D. Patents from USPTO. Publications from OpenAlex. Regulatory activity from the Federal Register. Press matched on company name.

How to read this page

Figures show associations in public records, not causes or predictions. Nothing here is investment advice. An em-dash means no record was found under this company's name, not that none exists.

Data freshness

SEC Form D filings through . SBIR and STTR awards through .